In an attempt to bolster its respiratory portfolio, GSK has agreed to acquire Aiolos Bio for US$1 B upfront and up to US$400 M in potential development milestones. Through the takeover, GSK will gain access to Aiolos’ novel monoclonal antibody, AIO-001, for the treatment of patients with certain respiratory and inflammatory conditions. The deal marks yet another move by the big pharma to bolster and diversify its pipeline in the respiratory space, as GSK looks to be less reliant on its marketed products which are approaching patent expiry later this decade.